Tenax Therapeutics Inc
TENX6.150USD
-0.070-1.13%
시장 운영 시간 （ET）시세는 15분 지연됩니다
24.42M시가총액
손실P/E TTM
자세한 내용은 Tenax Therapeutics Inc 회사
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
회사 정보
종목 코드 TENX
회사 이름Tenax Therapeutics Inc
상장일Oct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
직원 수4
유형Ordinary Share
회계 연도 종료Oct 28
주소101 Glen Lennox Drive
도시CHAPEL HILL
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호27517
전화19198552100
웹사이트http://www.tenaxthera.com/
종목 코드 TENX
상장일Oct 28, 1993
CEOMr. Christopher T. (Chris) Giordano
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
주주
주주
비율
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
주주 유형
주주
비율
Hedge Fund
30.53%
Investment Advisor/Hedge Fund
18.96%
Venture Capital
10.04%
Investment Advisor
9.19%
Research Firm
2.85%
Individual Investor
0.23%
Other
28.19%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
58
2.98M
71.81%
+994.85K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
2023Q1
49
16.81K
20.77%
+6.69K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RTW Investments L.P.
378.35K
9.12%
+378.35K
--
Mar 31, 2025
The Lind Partners, LLC
375.00K
9.04%
+305.00K
+435.71%
Sep 30, 2024
Dellora Investments LP
351.07K
8.46%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
8.18%
--
--
Mar 31, 2025
Millennium Management LLC
233.62K
5.63%
+206.99K
+777.40%
Jun 26, 2025
VR Adviser, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Vivo Capital, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
167.00K
4.03%
+167.00K
--
Mar 31, 2025
Janus Henderson Investors
166.67K
4.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
117.83K
2.84%
+45.66K
+63.27%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
날짜
유형
비율
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
